Global Immuno-oncology Clinical Trials Market Size & Outlook

The immuno-oncology clinical trials industry worldwide is expected to reach a projected revenue of US$ 18,656.8 million by 2030. A compound annual growth rate of 12.4% is expected of the worldwide immuno-oncology clinical trials industry from 2024 to 2030.

Revenue, 2023 (US$M)
$8,236.3
Forecast, 2030 (US$M)
$18,656.8
CAGR, 2024 - 2030
12.4%
Report Coverage
Worldwide

Global immuno-oncology clinical trials market highlights

  • The global immuno-oncology clinical trials market generated a revenue of USD 8,236.3 million in 2023 and is expected to reach USD 18,656.8 million by 2030.
  • The market is expected to grow at a CAGR (2024 - 2030) of 12.4% by 2030.
  • In terms of segment, phase iii accounted for a revenue of USD 4,414.6 million in 2023.
  • Phase I is the most lucrative phase segment registering the fastest growth during the forecast period.
  • In terms of region, North America was the largest revenue generating market in 2023.
  • Country-wise, France is expected to register the highest CAGR from 2024 to 2030.

Global data book summary

Market revenue in 2023USD 8,236.3 million
Market revenue in 2030USD 18,656.8 million
Growth rate12.4% (CAGR from 2023 to 2030)
Largest segmentPhase iii
Fastest growing segmentPhase I
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPhase I, Phase II, Phase III, Phase IV

Other key industry trends

  • In terms of revenue, the North America accounted for 50.3% of the global immuno-oncology clinical trials market in 2023.
  • By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
  • By country, France is the fastest growing regional market and is projected to reach USD 1,026.6 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Immuno-oncology Clinical Trials Market Companies

Name Profile # Employees HQ Website

Global immuno-oncology clinical trials market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immuno-oncology clinical trials market will help companies and investors design strategic landscapes.


phase iii was the largest segment with a revenue share of 53.6% in 2023. Horizon Databook has segmented the Global immuno-oncology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.


  • Global Immuno-oncology Clinical Trials Phase Outlook (Revenue, USD Million, 2018-2030)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Global Immuno-oncology Clinical Trials Design Outlook (Revenue, USD Million, 2018-2030)
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Global Immuno-oncology Clinical Trials Indication Outlook (Revenue, USD Million, 2018-2030)
    • Solid Tumors
    • Hematological Cancers

Reasons to subscribe to Global immuno-oncology clinical trials market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Global immuno-oncology clinical trials market databook

  • Our clientele includes a mix of immuno-oncology clinical trials market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of global-level data and insights on the Global immuno-oncology clinical trials market , including forecasts for subscribers. This global databook contains high-level insights into Global immuno-oncology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Global immuno-oncology clinical trials market statistics, by regions, 2018-2030 (US$M)

Top 10 countries: Immuno-oncology clinical trials market size, 2023 (USD Million)

Top 10 countries: Immuno-oncology clinical trials market size, 2023 (USD Million)

Global immuno-oncology clinical trials market, by region, 2023 (US$M)

Global immuno-oncology clinical trials market statistics, by regions, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more